Search

Your search keyword '"Zhong, HuaGe"' showing total 22 results
Start Over Author "Zhong, HuaGe"
22 results on '"Zhong, HuaGe"'

1. Thermal ablation with and without adjuvant systemic therapy: a nationwide multicenter observational cohort study of solitary colorectal liver metastases

Author

Li, Jianming, primary, Pang, Chuan, additional, Liu, Guangjian, additional, Xie, Xiaoyan, additional, Zhang, De-zhi, additional, Li, Kai, additional, Li, Zhishuai, additional, He, Guangbin, additional, Xu, Erjiao, additional, Zhong, Huage, additional, Yang, Hong, additional, Lu, Man, additional, Lou, Kexin, additional, Xie, Xiang, additional, Lan, Sirong, additional, Li, Qian, additional, Dai, Guanghai, additional, Yu, Jie, additional, and Liang, Ping, additional

Published
2024
Full Text
View/download PDF

4. Upfront Versus Delayed Thermal Ablation for Colorectal Liver Oligometastases: A Multicenter Retrospective Study Using Propensity-Score Matching

Author

Li, Jianming, primary, Yu, Jie, additional, Liu, Guangjian, additional, Xie, Xiaoyan, additional, Zhang, De-zhi, additional, Zheng, Rongqin, additional, Yang, Hong, additional, Zhong, Huage, additional, Lu, Shaolong, additional, Xiang, Hua, additional, Cai, Xiaoyong, additional, Dai, Guanghai, additional, Luo, Yanchun, additional, and Liang, Ping, additional

Published
2022
Full Text
View/download PDF

6. Ablation Combined With Systemic Treatment for Colorectal Liver Oligo-Metastases: What's the Optimal Sequencing?

Author

Li, Jianming, primary, Liu, Guangjian, additional, Xie, Xiaoyan, additional, Cui, Rui, additional, Zhuang, Bowen, additional, Ma, Jun, additional, Zhang, De-zhi, additional, Zheng, Rongqin, additional, Yang, Hong, additional, Zhong, Huage, additional, Xiang, Hua, additional, Cai, Xiaoyong, additional, Zhu, Yupeng, additional, Luo, Liping, additional, Zhang, Man, additional, Que, Qiao, additional, Cheng, Linyao, additional, Lu, Shaolong, additional, Yan, Mengfan, additional, Zhao, Bo, additional, Dai, Guanghai, additional, Qian, Niansong, additional, Gou, Miaomiao, additional, Yu, Xiao-ling, additional, Cheng, Zhi-gang, additional, Liu, Fang-yi, additional, Han, Zhi-yu, additional, Zhang, Jing, additional, Luo, Yanchun, additional, Yu, Jie, additional, and Liang, Ping, additional

Published
2022
Full Text
View/download PDF

7. Immune Signature-Based Risk Stratification and Prediction of Immunotherapy Efficacy for Bladder Urothelial Carcinoma

Author

Liang, Fangfang, Xu, Yansong, Chen, Yi, Zhong, Huage, Wang, Zhen, Nong, Tianwen, and Zhong, Jincai

Subjects
bladder urothelial carcinoma, tumor immune microenvironment, QH301-705.5, immune-related genes, immune checkpoint inhibitor, prognostic model, Molecular Biosciences, immunotherapy, Biology (General), Biochemistry, Genetics and Molecular Biology (miscellaneous), Molecular Biology, Biochemistry, Original Research
Abstract

Immune-related genes (IRGs) are closely related to tumor progression and the immune microenvironment. Few studies have investigated the effect of tumor immune microenvironment on the survival and response to immune checkpoint inhibitors of patients with bladder urothelial carcinoma (BLCA). We constructed two IRG-related prognostic signatures based on gene–immune interaction for predicting risk stratification and immunotherapeutic responses. We also verified their predictive ability on internal and overall data sets. Patients with BLCA were divided into high- and low-risk groups. The high-risk group had poor survival, enriched innate immune-related cell subtypes, low tumor mutation burden, and poor response to anti-PD-L1 therapy. Our prognostic signatures can be used as reliable prognostic biomarkers, which may be helpful to screen the people who will benefit from immunotherapy and guide the clinical decision-making of patients with BLCA.

Published
2021

8. Extracellular vesicles in Inter-Kingdom communication in gastrointestinal cancer

Author

Chen, Yi, Xu, Yansong, Zhong, Huage, Yuan, Hao, Liang, Fangfang, Liu, Junjie, and Tang, Weizhong

Subjects
Review Article
Abstract

The production and secretion of extracellular vesicles (EVs) are common features of cells (including various normal cells, neoplastic cell lines as well as bacteria) that span all domains of life. Tumor-derived exosomes are enriched with kinds of tumorigenesis mediators which are derived from the cytoplasm of cancer cells and fully reflect the tumor conditions. Indeed, the major topics and challenges on current oncological research are the identification of tumorigenic and metastatic molecules in tumor-cell-derived exosomes as well as elucidating the pathways that guarantee these components to be included in exosomes. The bacterial EVs have also been implicated in the pathogenesis of gastrointestinal (GI) tumors and chronic inflammatory diseases; however, the possible function of outer membrane vesicles (OMVs) in tumorigenesis remains largely underestimated. We suggest that EVs from both eukaryotic cells and different microbes in GI tract act as regulators of intracellular and cross-species communication, thus particularly facilitate tumor cell survival and multi-drug resistance. Therefore, our review introduces comprehensive knowledge on the promising role of EVs (mainly exosomes and OMVs) production of GI cancer development and gut microbiome, as well as its roles in developing novel therapeutic strategies.

Published
2021

11. Circular RNA Profiling Reveals That circRNA_104433 Regulates Cell Growth by Targeting miR-497-5p in Gastric Cancer [Corrigendum]

Author

Wei,Weiyuan, Mo,Xianwei, Yan,Linhai, Huang,Mingwei, Yang,Yang, Jin,Qinwen, Zhong,Huage, Cao,Wenlong, Wu,Kun, Wu,Liucheng, Li,Zhao, Wang,Tingan, Qin,Yuzhou, and Chen,Jiansi

Subjects
Cancer Management and Research
Abstract

Wei W, Mo X, Yan L, et al. Cancer Manag Res.2020;12:15—30. The authors have advised there are errors in Figures 3and 5. Figure 3, page 24. The key in parts B and C have thelabels of “823-Si-circRNA_0005039” and “7901-SicircRNA_0005039” which should read “823-SicircRNA_104433” and “7901-Si-circRNA_104433”,respectively. The correct Figure 3 is shown below. Figure 5, page 26. The Y axis in part E has the label of“The relative expression of miR-593-5p” which shouldread “The relative expression of miR-497-5p”. The correctFigure 5 is shown below. Read the original article

Published
2020

19. Evaluation of Red Cell Distribution Width to Lymphocyte Ratio as Potential Biomarker for Detection of Colorectal Cancer

Author

Huang, Jiahao, primary, Zhao, Yang, additional, Liao, Lin, additional, Liu, Shun, additional, Lu, Shaolong, additional, Wu, Changtao, additional, Wei, Chuanyi, additional, Xu, Shaoqiang, additional, Zhong, Huage, additional, Liu, Junjie, additional, Guo, Yun, additional, Zhang, Sen, additional, Gao, Feng, additional, and Tang, Weizhong, additional

Published
2019
Full Text
View/download PDF

21. Up-Front Versus Delayed Thermal Ablation for Colorectal Liver Oligometastases: A Multicenter Retrospective Study Using Propensity Score Matching.

Author

Li J, Yu J, Liu G, Xie X, Zhang DZ, Zheng R, Yang H, Zhong H, Lu S, Xiang H, Cai X, Dai G, Luo Y, and Liang P

Subjects
Male, Humans, Female, Middle Aged, Aged, Retrospective Studies, Treatment Outcome, Propensity Score, Liver pathology, Liver Neoplasms pathology, Colorectal Neoplasms pathology
Abstract

BACKGROUND. Thermal ablation combined with systemic therapy is an accepted treatment of colorectal liver oligometastases (CLOM). Consensus is lacking regarding the optimal timing of thermal ablation relative to systemic therapy. OBJECTIVE. The purpose of our study was to compare delayed and up-front thermal ablation in terms of efficacy and safety in the treatment of patients with CLOM. METHODS. This retrospective multicenter study included 440 patients (316 men, 124 women; mean age, 57.1 ± 11.1 [SD] years) with CLOM from nine hospitals between October 2009 and December 2020. Patients underwent delayed ( n = 322) or up-front ( n = 118) thermal ablation in combination with systemic therapy. Analyses included all patients using crude data, all patients using inverse probability treatment weighting (IPTW), and a subset of patients using propensity score matching (PSM) at a 1:1 ratio to balance baseline variables (108 matched patients for each group [i.e., delayed ablation and up-front ablation]). Patients were classified as having a low or high tumor burden score (TBS) on the basis of the number and size of the liver metastases. The primary outcome was progression-free survival (PFS); secondary outcomes included overall survival (OS), complications from ablation, and adverse events (AEs) from systemic therapy. Survival analysis used the Kaplan-Meier method. RESULTS. The median follow-up was 2.9 years. The 5-year PFS was 17.1% for delayed ablation versus 33.6% for up-front ablation in all patients and 17.9% versus 34.7% after PSM. Delayed ablation was associated with worse PFS in the crude analysis (HR = 0.62), IPTW analysis (HR = 0.66), and PSM analysis (HR = 0.62) (all p < .05). No analysis showed a significant difference in OS between delayed and up-front ablation. Crude, IPTW, and PSM analyses showed better PFS for up-front compared with delayed ablation in patients with a low TBS (HR = 0.62-0.67; all p < .05); none of these analyses showed significant difference in PFS in patients with a high TBS. Delayed ablation and up-front ablation groups showed no difference in frequency of grade III or IV ablation complications (4.7% vs 6.8%, p = .38) or grade III or IV systemic therapy AEs (12.4% vs 10.2%, p = .53). CONCLUSION. In patients with CLOM, up-front ablation achieved better PFS compared with delayed ablation, although only among patients with a low TBS. CLINICAL IMPACT. These findings could help optimize clinical implementation of thermal ablation in patients who are not candidates for surgical resection.

Published
2023
Full Text
View/download PDF

22. Extracellular vesicles in Inter-Kingdom communication in gastrointestinal cancer.

Author

Chen Y, Xu Y, Zhong H, Yuan H, Liang F, Liu J, and Tang W

Abstract

The production and secretion of extracellular vesicles (EVs) are common features of cells (including various normal cells, neoplastic cell lines as well as bacteria) that span all domains of life. Tumor-derived exosomes are enriched with kinds of tumorigenesis mediators which are derived from the cytoplasm of cancer cells and fully reflect the tumor conditions. Indeed, the major topics and challenges on current oncological research are the identification of tumorigenic and metastatic molecules in tumor-cell-derived exosomes as well as elucidating the pathways that guarantee these components to be included in exosomes. The bacterial EVs have also been implicated in the pathogenesis of gastrointestinal (GI) tumors and chronic inflammatory diseases; however, the possible function of outer membrane vesicles (OMVs) in tumorigenesis remains largely underestimated. We suggest that EVs from both eukaryotic cells and different microbes in GI tract act as regulators of intracellular and cross-species communication, thus particularly facilitate tumor cell survival and multi-drug resistance. Therefore, our review introduces comprehensive knowledge on the promising role of EVs (mainly exosomes and OMVs) production of GI cancer development and gut microbiome, as well as its roles in developing novel therapeutic strategies., Competing Interests: None., (AJCR Copyright © 2021.)

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results